Equities researchers at HC Wainwright issued their FY2029 earnings estimates for shares of Daré Bioscience in a research note ...
HC Wainwright issued their FY2029 EPS estimates for CG Oncology in a note issued to investors on Monday, March 31st. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings ...
22h
Fintel on MSNHC Wainwright & Co. Initiates Coverage of Kairos Pharma (KAPA) with Buy RecommendationFintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...
H.C. Wainwright analyst Douglas Tsao views the agreement of joint stipulation between Arcutis Biotherapeutics (ARQT) and Padagis to the ongoing ...
H.C. Wainwright initiated coverage of Kairos Pharma (KAPA) with a Buy rating and $12 price target The company’s oncology pipeline “could ...
1d
Fintel on MSNHC Wainwright & Co. Upgrades Sarepta Therapeutics (SRPT)Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...
Surf Air Mobility Inc. (NYSE: SRFM) (the "Company"), a leading regional air mobility platform, closed on the previously announced purchase and sale of 2,000,000 shares of common stock (or pre-funded ...
Knightscope, Inc. (NASDAQ: KSCP), a leader in developing autonomous security robots and artificial intelligence technologies, closed on the previously announced sale of an aggregate of 625,000 shares ...
Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results